El Fakih Riad, Ahmed Syed, Alfraih Feras, Hanbali Amr
Oncology Centre, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Oncology Centre, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Hematol Oncol Stem Cell Ther. 2017 Dec;10(4):252-258. doi: 10.1016/j.hemonc.2017.05.015. Epub 2017 Jun 15.
Acute lymphoblastic leukemia (ALL) consists of precursor B ALL or T ALL phenotypes. In the pediatric population, ALL patients enjoy an 80% long-term survival with the current pediatric chemotherapy protocols as compared with 50% long-term survival in the adult population. In adults, complete remission rates are similar to those of pediatric patients; however, long-term survival is much lower with the majority of deaths attributable to relapsed disease. Postremission consolidation strategies in adults include chemotherapy, autologous, or allogeneic transplant. Pediatric-inspired chemotherapy protocols are being explored as a consolidation modality in adults. Assigning patients to either modality depends on patient and disease characteristics. Here, we review the literature on the use of hematopoietic cell transplantation as a consolidation modality in the treatment of adult ALL.
急性淋巴细胞白血病（ALL）由前驱B淋巴细胞白血病或T淋巴细胞白血病表型组成。在儿科人群中，采用当前的儿科化疗方案，ALL患者的长期生存率为80%，而成人患者的长期生存率为50%。在成人中，完全缓解率与儿科患者相似；然而，长期生存率要低得多，大多数死亡归因于疾病复发。成人缓解后巩固策略包括化疗、自体或异基因移植。正在探索以儿科化疗方案为基础的巩固方式用于成人。将患者分配至任何一种方式都取决于患者和疾病特征。在此，我们综述了关于造血细胞移植作为巩固方式用于治疗成人ALL的文献。
